...
首页> 外文期刊>Journal of Clinical Medicine Research >Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow-Up Study
【24h】

Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow-Up Study

机译:溶栓治疗在急性亚大规模肺栓塞中的疗效和安全性:随访研究

获取原文

摘要

Background: Thrombolysis in acute submassive pulmonary embolism (PE) remains controversial. So we studied impact of thrombolytic therapy in acute submassive PE in terms of mortality, hemodynamic status, improvement in right ventricular function, and safety in terms of major and minor bleeding.Method: A single-center, prospective, randomized study of 86 patients was conducted at LPS Institute of Cardiology, G.S.V.M. Medical College, Kanpur, India. Patients received thrombolysis (single bolus of tenecteplase) with unfractionated heparin (UFH, group I) or placebo with UFH (group II).Result: Mean age of patients was 54.35 ± 12.8 years with male dominance (M:F = 70%:30%). Smoking was the most common risk factor seen in 29% of all patients, followed by recent history of immobilization (25%), history of surgery or major trauma within past 1 month (15%), dyslipidemia (10%) and diabetes mellitus (10%). Dyspnea was the most common symptom in 80% of all patients, followed by chest pain in 55% and syncope in 6%. Primary efficacy outcome occurred significantly better in group I vs. group II (4.5% vs. 20%; P = 0.04), and significant difference was also found in hemodynamic decompensation (4.5% vs. 20%; P = 0.04), the fall in mean pulmonary artery systolic pressure (PASP) (28.8% vs. 22.5%; P = 0.03), improvement in right ventricular (RV) function (70% vs. 40%; P = 0.001) and mean hospital stay (8.1 ± 2.5 vs. 11.1 ± 2.14 days; P = 0.001). There was no difference in mortality and major bleeding as safety outcome but increased minor bleeding occurred in group I patients (16% vs. 12%; P = 0.04).Conclusion: Patients with acute submassive PE do not derive overall mortality benefit, recurrent PE and rehospitalization with thrombolytic therapy but had improved clinical outcome in form of decrease in hemodynamic decompensation, mean hospital stay, PASP and improvement of RV function with similar risk of major bleed but at cost of increased minor bleeding.J Clin Med Res. 2017;9(2):163-169doi: https://doi.org/10.14740/jocmr2829w
机译:背景:急性亚大规模肺栓塞(PE)溶栓仍存在争议。因此,我们从死亡率,血液动力学状态,右心室功能的改善以及大出血和小出血的安全性等方面研究了溶栓治疗对急性亚大规模PE的影响。方法:对86例患者进行了单中心,前瞻性,随机研究。在GSVM LPS心脏病研究所进行印度坎普尔医学院。患者接受普通肝素(UFH,I组)溶栓治疗(单次替奈普酶)或UFH(II组)安慰剂治疗。结果:患者的平均年龄为54.35±12.8岁,男性占主导地位(M:F = 70%:30 %)。在所有患者中,吸烟是最常见的危险因素,占所有患者的29%,其次是近期的固定病史(25%),过去1个月内有手术或重大外伤史(15%),血脂异常(10%)和糖尿病( 10%)。呼吸困难是所有患者中最常见的症状,占80%,其次是胸痛,占55%,晕厥为6%。第一组疗效优于第二组(4.5%vs. 20%; P = 0.04),在血流动力学失代偿方面也有显着差异(4.5%vs. 20%; P = 0.04),下降平均肺动脉收缩压(PASP)(28.8%vs. 22.5%; P = 0.03),右心室(RV)功能改善(70%vs. 40%; P = 0.001)和平均住院时间(8.1±2.5)与11.1±2.14天; P = 0.001)。死亡率和作为安全性结果的大出血无差异,但I组患者发生的小出血增加(16%vs. 12%; P = 0.04)。溶栓治疗和再次住院治疗,但以减少血流动力学失代偿,平均住院时间,PASP和RV功能改善的形式改善了临床结局,具有类似的大出血风险,但以增加轻微出血为代价。 2017; 9(2):163-169doi:https://doi.org/10.14740/jocmr2829w

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号